175 related articles for article (PubMed ID: 35462031)
1. Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era.
Catania C; Piperno G; Russo A; Greco C; Agustoni F; Scotti V; Proto C; Sangalli C; Patani F; Santacaterina A; Di Pietro Paolo M; Agresti B; Filippi AR; Ramella S
Crit Rev Oncol Hematol; 2022 Jun; 174():103684. PubMed ID: 35462031
[TBL] [Abstract][Full Text] [Related]
2. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group.
Catania C; Filippi AR; Sangalli C; Piperno G; Russano M; Greco C; Scotti V; Proto C; Bennati C; Di Pietro Paolo M; Platania A; Olmetto E; Agustoni F; Teodorani N; Agbaje V; Russo A
Crit Rev Oncol Hematol; 2023 Oct; 190():104108. PubMed ID: 37633350
[TBL] [Abstract][Full Text] [Related]
3. The role of chemoradiotherapy and immunotherapy in stage III NSCLC.
Orosz Z; Kovács Á
Pathol Oncol Res; 2024; 30():1611716. PubMed ID: 38706775
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations.
Cortiula F; De Ruysscher D; Steens M; Wijsman R; van der Wekken A; Alberti M; Hendriks LEL
Eur J Cancer; 2023 May; 184():172-178. PubMed ID: 36931075
[TBL] [Abstract][Full Text] [Related]
5. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
[TBL] [Abstract][Full Text] [Related]
6. Rationale and Design of a Single-Arm, Phase 2, Multi-Center Study of Chemo-Immunotherapy Followed by Hypo-Fractionated RT and Maintenance Immunotherapy in Patients With Unresectable Stage III NSCLC: The DEDALUS Trial.
Filippi AR; Agustoni F; Arcangeli S; Cortinovis D; Ferrari A; Cicognini D; Saddi J; Klersy C; Pedrazzoli P; Malapelle U; Grossi F
Clin Lung Cancer; 2023 May; 24(3):e122-e125. PubMed ID: 36759266
[TBL] [Abstract][Full Text] [Related]
7. The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer.
Perdrizet K; Cheema PK
Curr Oncol; 2021 Dec; 28(6):5408-5421. PubMed ID: 34940090
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
Kaira K; Mouri A; Kato S; Yoshimura K; Kagamu H; Kobayashi K
BMC Cancer; 2020 Oct; 20(1):961. PubMed ID: 33023530
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
10. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches.
Cortiula F; Reymen B; Peters S; Van Mol P; Wauters E; Vansteenkiste J; De Ruysscher D; Hendriks LEL
Ann Oncol; 2022 Sep; 33(9):893-908. PubMed ID: 35777706
[TBL] [Abstract][Full Text] [Related]
12. Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
Puri S; Saltos A; Perez B; Le X; Gray JE
Curr Oncol Rep; 2020 Mar; 22(4):31. PubMed ID: 32140986
[TBL] [Abstract][Full Text] [Related]
13. Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial.
Ko JJ; Banerji S; Blais N; Brade A; Clelland C; Schellenberg D; Snow S; Wheatley-Price P; Yuan R; Melosky B
Curr Oncol; 2023 Mar; 30(4):3817-3828. PubMed ID: 37185402
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
15. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
16. A case report of sustained clinical remission in patients with locally advanced lung adenocarcinoma after sequential immunotherapy following concurrent chemoradiotherapy.
Chen W; Zhang H; Huang W; Lan T
Ann Palliat Med; 2020 Nov; 9(6):4346-4352. PubMed ID: 33302686
[TBL] [Abstract][Full Text] [Related]
17. Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy.
Moore S; Leung B; Wu J; Ho C
J Thorac Oncol; 2019 Aug; 14(8):1430-1439. PubMed ID: 31002953
[TBL] [Abstract][Full Text] [Related]
18. Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: a review.
Baldini E; Tibaldi C; Delli Paoli C
Clin Transl Oncol; 2020 Oct; 22(10):1681-1686. PubMed ID: 32128671
[TBL] [Abstract][Full Text] [Related]
19. Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.
Zhu L; Zou C; Zhang Z; Wang J; Yang L; Rao C; Yang Z; Liang J; Xia B; Shenglin MA
BMC Cancer; 2021 May; 21(1):511. PubMed ID: 33962566
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
